Changes in research practice during the COVID-19 pandemic necessitates renewed attention to ethical protocols and reporting for data collection on sensitive topics. We systematically searched journal publications from the start of the pandemic to November 2021, identifying 75 studies that collected primary data on violence against women and children. We assess the transparency of ethics reporting and adherence to relevant guidelines against a 14-item checklist of best practices. Studies reported adhering to best practices on 31% of scored items with highest reporting for ethical clearance (87%) and informed consent/assent (84/83%) and lowest reporting for facilitating referrals for minors and soliciting participant feedback (both 0%). Violence studies of primary data collected during COVID-19 report on few ethical standards, obscuring stakeholder ability to enforce a “do no harm” approach and to assess the reliability of findings. We offer recommendations and guidelines to improve future reporting and implementation of ethics within violence studies.
Objectives: The rapid pace, high volume, and limited quality of mental health evidence that has been generated during COVID-19 poses a barrier to understanding mental health outcomes. We sought to summarize results from studies that compared mental health outcomes during COVID-19 to outcomes assessed prior to COVID-19 in the same cohort in the general population and in other groups for which data have been reported. Design: Living systematic review. Data Sources: MEDLINE (Ovid), PsycINFO (Ovid), CINAHL (EBSCO), EMBASE (Ovid), Web of Science Core Collection: Citation Indexes, China National Knowledge Infrastructure, Wanfang, medRxiv (preprints), and Open Science Framework Preprints (preprint server aggregator). Eligibility criteria for selecting studies: For this report, we included studies that compared general mental health, anxiety symptoms, or depression symptoms, assessed January 1, 2020 or later, to the same outcomes collected between January 1, 2018 and December 31, 2019. Any population was eligible. We required ≥ 90% of participants pre-COVID-19 and during COVID-19 to be the same or the use of statistical methods to address missing data. For population groups with continuous outcomes for at least two studies in an outcome domain, we conducted restricted maximum-likelihood random-effects meta-analyses. Worse COVID-19 mental health outcomes are reported as positive. Risk of bias of included studies was assessed using an adapted version of the Joanna Briggs Institute Checklist for Prevalence Studies. Results: As of April 11, 2022, we had reviewed 94,411 unique titles and abstracts and identified 137 unique eligible studies with data from 134 cohorts. Almost all studies were from high-income (105, 77%) or upper-middle income (28, 20%) countries. Among adult general population studies, we did not find changes in general mental health (standardized mean difference of change [SMDchange = 0.11, 95% CI -0.00 to 0.22) or anxiety symptoms (SMDchange = 0.05, 95% CI -0.04 to 0.13), but depression symptoms worsened minimally (SMDchange = 0.12, 95% CI 0.01 to 0.24). Among women or females, mental health symptoms worsened by minimal to small amounts in general mental health (SMDchange = 0.22, 95% CI 0.08 to 0.35), anxiety symptoms (SMDchange = 0.20, 95% CI 0.12 to 0.29), and depression symptoms (SMDchange = 0.22, 95% CI 0.05 to 0.40). Of 27 other analyses across outcome domains, among subgroups other than women or females, 5 analyses suggested minimal or small amounts of symptom worsening, and 2 suggested minimal or small symptom improvements. No other subgroup experienced statistically significant changes across outcome domains. In the 3 studies with data from March to April 2020 and later in 2020, symptoms either were unchanged from pre-COVID-19 at both time points or increased initially then returned to pre-COVID-19 levels. Heterogeneity measured by the I2 statistic was high (e.g., > 80%) for most analyses, and there was concerning risk of bias in most studies. Conclusions: High risk of bias in many studies and substantial heterogeneity suggest that point estimates should be interpreted cautiously. Nonetheless, there was general consistency across analyses in that most symptom change estimates were close to zero and not statistically significant, and changes that were identified were of minimal to small magnitudes. There were, however, small negative changes for women or females in all domains. It is possible that gaps in data have not allowed identification of changes in some vulnerable groups. Continued updating is needed as evidence accrues. Funding: Canadian Institutes of Health Research (CMS-171703; MS1-173070; GA4-177758; WI2-179944); McGill Interdisciplinary Initiative in Infection and Immunity Emergency COVID-19 Research Fund (R2-42). Registration: PROSPERO (CRD42020179703); registered on April 17, 2020.
Since the emergence of Omicron, reinfections with SARS-CoV-2 have been rising. We estimated the risk of SARS-CoV-2 reinfection in the widely vaccinated French population, from January to August 2022. At nine weeks post-infection, the relative risk of reinfection, primary infection with pre-Delta variants being the reference group, was estimated at 0.43 [95%CI 0.40-0.47] if the primary infection was attributed to Delta, 0.21 [95%CI 0.19-0.24] with BA.1 and 0.17 [95% CI 0.15-0.18] with BA.2, and rapidly waned overtime. After a BA.1 primary infection the protection was similar against BA.2 or BA.4/5 reinfection.
Background During the first two years of the COVID-19 pandemic, the circulation of seasonal influenza viruses was unprecedentedly low. This led to concerns that the lack of immune stimulation to influenza viruses combined with waning antibody titres could lead to increased susceptibility to influenza in subsequent seasons, resulting in larger and more severe epidemics. Methods We analyzed historical influenza virus epidemiological data from 2003-2019 to assess the historical frequency of near-absence of seasonal influenza virus circulation and its impact on the size and severity of subsequent epidemics. Additionally, we measured haemagglutination inhibition-based antibody titres against seasonal influenza viruses using longitudinal serum samples from 165 healthy adults, collected before and during the COVID-19 pandemic, and estimated how antibody titres against seasonal influenza waned during the first two years of the pandemic. Findings Low country-level prevalence of influenza virus (sub)types over one or more years occurred frequently before the COVID-19 pandemic and had relatively small impacts on subsequent epidemic size and severity. Additionally, antibody titres against seasonal influenza viruses waned negligibly during the first two years of the pandemic. Interpretation The commonly held notion that lulls in influenza virus circulation, as observed during the COVID-19 pandemic, will lead to larger and/or more severe subsequent epidemics might not be fully warranted, and it is likely that post-lull seasons will be similar in size and severity to pre-lull seasons. Funding European Research Council, Netherlands Organization for Scientific Research, Royal Dutch Academy of Sciences, Public Health Service of Amsterdam.
The continuing emergence of SARS-CoV-2 variants of concern (VOCs) presents a serious public health threat, exacerbating the effects of the COVID19 pandemic. Although millions of genomes have been deposited in public archives since the start of the pandemic, predicting SARS-CoV-2 clinical characteristics from the genome sequence remains challenging. In this study, we used a collection of over 29,000 high quality SARS-CoV-2 genomes to build machine learning models for predicting clinical detection cycle threshold (Ct) values, which correspond with viral load. After evaluating several machine learning methods and parameters, our best model was a random forest regressor that used 10-mer oligonucleotides as features and achieved an R2 score of 0.521 +/- 0.010 (95% confidence interval over 5 folds) and an RMSE of 5.7 +/- 0.034, demonstrating the ability of the models to detect the presence of a signal in the genomic data. In an attempt to predict Ct values for newly emerging variants, we predicted Ct values for Omicron variants using models trained on previous variants. We found that approximately 5% of the data in the model needed to be from the new variant in order to learn its Ct values. Finally, to understand how the model is working, we evaluated the top features and found that the model is using a multitude of k-mers from across the genome to make the predictions. However, when we looked at the top k-mers that occurred most frequently across the set of genomes, we observed a clustering of k-mers that span spike protein regions corresponding with key variations that are hallmarks of the VOCs including G339, K417, L452, N501, and P681, indicating that these sites are informative in the model and may impact the Ct values that are observed in clinical samples.
We isolated infectious SARS-CoV-2 from aerosol samples collected from hospital rooms of COVID19 patients. Isolated virus successfully replicated in cell cultures 14 months after collection, opening up prospects for retrospective analyses of samples stored during the previous waves of COVID-19.
Objectives: The Corona Virus Disease-2019 (COVID-19) pandemic has psychological consequences such as increased risk of depression, anxiety, and stress problems, exacerbating human health disparities. This study aimed to analyze depression and its causes in COVID-19-recovered patients in Bangladesh. Method: A cross-sectional study was conducted on COVID-19 recovered patients, who attended for follow-up after 14 days to 3 months at Dhaka Medical College Hospital (DMCH) and Dhaka North City Corporation Hospital (DNCCH), Dhaka, Bangladesh from 1st January to 31st December, 2021. Respondents were face-to-face interviewed with a semi-structured questionnaire after written agreement. The Patient Health Questionnaire (PHQ-9) was used to assess respondents9 depression, and data were analyzed using SPSS version-23, with p < 0.05 indicating statistical significance. Results: A total of 325 COVID-19 recovered patients aged from 15 to 65 years (mean 44.34 ±13.87 years) of age were included in this study, highest 23.1% of them belonged to 46-55 years, and majority (61.5%) of them were male. There were 69.5% of respondents had no signs of depression while 31% of them had with 26.7% being mildly depressed, 2.5% being extremely depressed, and 1.2% being severely depressed. Diabetes mellitus, hospitalization duration, social distancing, the social media post on COVID-19, loss of employment, family damage, and fear of re-infection were significantly associated with depression level of respondents. Conclusion: This study gives us a glimpse into the psychological health of COVID-19 recovered patients, and its findings highlight the imperative of alleviating their psychological anguish in Bangladesh.
COVID-19 Bivalent Booster Megastudy - Condition: COVID-19
Intervention: Behavioral: COVID Booster text messages
Sponsor: University of Pennsylvania
Enrolling by invitation
A Study on Utilization, Adherence, and Acceptability of Voluntary Routine COVID-19 Self-testing Among Students, Staff and Health Workers at Two Institutions in Mizoram, India. - Condition: COVID-19 Pandemic
Intervention: Diagnostic Test: COVID-19 Self testing and related messaging
Sponsors: PATH; UNITAID; Zoram Medical College; Pacchunga University College; ALERT India; Government of Mizoram
Not yet recruiting
Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities - Condition: COVID-19
Interventions: Behavioral: Multi-Level Multi-Component Intervention (MLI); Behavioral: Community Just-In-Time Adaptive Intervention (Community JITAI)
Sponsors: The University of Texas Health Science Center, Houston; National Center for Advancing Translational Sciences (NCATS)
Active, not recruiting
Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing - Condition: COVID-19
Interventions: Behavioral: Facilitated Self-Sampling Intervention (FSSI); Behavioral: Testing Navigation Intervention (TNI).; Behavioral: Control
Sponsors: The University of Texas Health Science Center, Houston; National Center for Advancing Translational Sciences (NCATS)
Not yet recruiting
Assessing Performance of the Testing Done Simple Covid 19 Antigen Test - Condition: COVID-19
Intervention: Diagnostic Test: Testing Done Simple SARS CoV-2 Antigen Test
Sponsors: Testing Done Simple; Nao Medical Urgent Care
Recruiting
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 - Condition: COVID-19
Interventions: Drug: EDP-235; Drug: Placebo
Sponsor: Enanta Pharmaceuticals, Inc
Recruiting
The LAVA (Lateral Flow Antigen Validation and Applicability) 2 Study for COVID-19 - Condition: SARS-CoV-2 Infection
Intervention: Diagnostic Test: Innova Lateral Flow Test
Sponsor: Alder Hey Children’s NHS Foundation Trust
Completed
Q-POC COVID-19 Clinical Evaluation - Condition: COVID-19
Interventions: Diagnostic Test: RT-PCR Test; Diagnostic Test: Real-time PCR Test
Sponsors: QuantuMDx Group Ltd; EDP Biotech; Paragon Rx Clinical; PathAI; PRX Research and Development
Not yet recruiting
Enhancing Protection Against Influenza and COVID-19 for Pregnant Women and Medically at Risk Children - Conditions: Influenza; COVID-19
Intervention: Behavioral: Nudge
Sponsor: University of Adelaide
Recruiting
Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers - Condition: COVID-19
Interventions: Biological: Avacc 10; Combination Product: Outer Membrane Vesicles (OMV) : OMV alone in vehicle; Other: Placebo
Sponsors: Intravacc B.V.; Novotech (Australia) Pty Limited
Not yet recruiting
A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) - Condition: COVID-19
Interventions: Biological: Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells); Biological: Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Recruiting
COVID-19 Antibody Responses in Cystic Fibrosis - Conditions: COVID-19; Cystic Fibrosis
Intervention: Biological: Blood sample
Sponsors: Hospices Civils de Lyon; Queen’s University, Belfast
Recruiting
A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster - Condition: COVID-19 Pandemic
Interventions: Biological: Lyophilized COVID-19 mRNA Vaccine; Drug: Sodium chloride
Sponsors: Wuhan Recogen Biotechnology Co., Ltd.; Shenzhen Rhegen Biotechnology Co., Ltd.; Wuhan Rhegen Biotechnology Co., Ltd.
Not yet recruiting
Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults - Condition: COVID-19, SARS CoV 2 Infection
Interventions: Biological: ChulaCov19 BNA159 vaccine (50 mcg); Biological: Pfizer/BNT vaccine (30 mcg)
Sponsors: Technovalia, Pty Ltd; Chulalongkorn University; BioNet-Asia; Southern Star Research Pty Ltd.
Not yet recruiting
Message From Local Pharmacy Team - Condition: COVID-19
Intervention: Behavioral: COVID Booster text messages
Sponsor: University of Pennsylvania
Enrolling by invitation
Repositioning of anti-dengue compounds against SARS-CoV-2 as viral polyprotein processing inhibitor - A therapy for COVID-19 (Coronavirus Disease 19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) remains elusive due to the lack of an effective antiviral therapeutic molecule. The SARS-CoV-2 main protease (Mpro), which plays a vital role in the viral life cycle, is one of the most studied and validated drug targets. In Several prior studies, numerous possible chemical entities were proposed as potential Mpro inhibitors; however, most failed at various stages of drug…
Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial - CONCLUSION: Colchicine was not found to have a significant beneficial effect on reducing mortality and the need for mechanical ventilation. However, a delayed beneficial effect was observed. Therefore, further studies should be conducted to evaluate the late benefits of colchicine.
SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression - Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of VOC remain understudied. Here, we provide an extensive functional study of VOC Alpha replication and cell entry phenotypes assisted by reverse genetics, mutational mapping of spike in lentiviral pseudotypes, viral and cellular gene expression studies, and…
Contribution of Chinese herbal medicine in the treatment of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of randomized controlled trials - Coronavirus disease 2019 (COVID-19) has become a global epidemic, and there is no specific treatment for anti-COVID-19 drugs. However, treatment of COVID-19 using Chinese herbal medicine (CHM) has been widely practiced in China. PubMed, Embase, Cochrane Library, CNKI, Wanfang and VIP databases were searched to evaluate the efficacy and safety of CHM in the treatment of COVID-19. Twenty-six studies were included in this meta-analysis. The included cases were all patients diagnosed with COVID-19…
Evaluation of the anti-diabetic drug sitagliptin as a novel attenuate to SARS-CoV-2 evidence-based in silico: molecular docking and molecular dynamics - The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein…
In Silico and In Vitro studies of taiwan chingguan yihau (NRICM101) on TNF-α/IL-1β-induced human lung cells - COVID-19 pandemic has been a global outbreak of coronavirus (SARS-CoV-2 virus) since 2019. Taiwan Chingguan Yihau (NRICM101) is the first traditional Chinese medicine (TCM) classic herbal formula and is widely used for COVID-19 patients in Taiwan and more than 50 nations. This study is to investigate in silico target fishing for the components of NRICM101 and to explore whether NRICM101 inhibits cytokines-induced normal human lung cell injury in vitro. Our results showed that network prediction…
Comparison of RT-qPCR and RT-dPCR Platforms for the Trace Detection of SARS-CoV-2 RNA in Wastewater - We compared reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and RT digital PCR (RT-dPCR) platforms for the trace detection of SARS-CoV-2 RNA in low-prevalence COVID-19 locations in Queensland, Australia, using CDC N1 and CDC N2 assays. The assay limit of detection (ALOD), PCR inhibition rates, and performance characteristics of each assay, along with the positivity rates with the RT-qPCR and RT-dPCR platforms, were evaluated by seeding known concentrations of exogenous…
GLUCOSE AND MANNOSE ANALOGS INHIBIT KSHV REPLICATION BY BLOCKING N-GLYCOSYLATION AND INDUCING THE UNFOLDED PROTEIN RESPONSE - Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent for Kaposi’s sarcoma (KS), an HIV/AIDS-associated malignancy. Effective treatments against KS remain to be developed. The sugar analog 2-deoxy-d-glucose (2-DG) is an anti-cancer agent that is well-tolerated and safe in patients and was recently demonstrated to be a potent antiviral, including KSHV and SARS-Cov-2. Because 2-DG inhibits glycolysis and N-glycosylation, identifying its molecular targets is challenging. Here we…
Differential upregulation of AU-rich element-containing mRNAs in COVID-19 - CONCLUSIONS: Compared to the rest of the transcriptome, ARE-containing mRNAs are preferentially upregulated in response to viral infections at a global level. In the context of COVID-19, they are most upregulated in mild disease. Due to their large number, their levels measured by RNA-seq may provide a reliable indication of COVID-19 severity.
SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly - CTL-mediated killing of virally infected or malignant cells is orchestrated at the immune synapse (IS). We hypothesized that SARS-CoV-2 may target lytic IS assembly to escape elimination. We show that human CD8+ T cells upregulate the expression of ACE2, the Spike receptor, during differentiation to CTLs. CTL preincubation with the Wuhan or Omicron Spike variants inhibits IS assembly and function, as shown by defective synaptic accumulation of TCRs and tyrosine phosphoproteins as well as…
Charge-Dependent Signal Changes for Label-Free Electrochemiluminescence Immunoassays - Label-free electrochemiluminescence (ECL) immunoassays (lf-ECLIA), based on biomarker-induced ECL signal changes, have attracted increasing attention due to the simple, rapid, and low-cost detection of biomarkers without secondary antibodies and complicated labeling procedures. However, the interaction rule and mechanism between analytical interfaces and biomarkers have rarely been explored. Herein, the interactions between biomarkers and analytical interfaces constructed by assembly of a…
Rational Development of Hypervalent Glycan Shield-Binding Nanoparticles with Broad-Spectrum Inhibition against Fatal Viruses Including SARS-CoV-2 Variants - Infectious virus diseases, particularly coronavirus disease 2019, have posed a severe threat to public health, whereas the developed therapeutic and prophylactic strategies are seriously challenged by viral evolution and mutation. Therefore, broad-spectrum inhibitors of viruses are highly demanded. Herein, an unprecedented antiviral strategy is reported, targeting the viral glycan shields with hypervalent mannose-binding nanoparticles. The nanoparticles exhibit a unique double-punch mechanism,…
DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation - Cellular infections by DNA viruses trigger innate immune responses mediated by DNA sensors. The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon gene (STING) signaling pathway has been identified as a DNA-sensing pathway that activates interferons in response to viral infection and, thus, mediates host defense against viruses. Previous studies have identified oncogenes E7 and E1A of the DNA tumor viruses, human papillomavirus 18 (HPV18) and adenovirus, respectively, as inhibitors of the…
Favipiravir Efficacy And Safety For The Treatment Of Severe Coronavirus Disease 2019: A Retrospective Study - CONCLUSIONS: In this study, Favipiravir showed better therapeutic responses in patients with severe COVID-19 infection, in terms of average duration of stay in the intensive care unit and was well tolerated in the younger age, but showed no mortality benefit. However, elevated levels of inflammatory markers, including increased ALT, AST, BUN, bilirubin, and creatinine, needs to be carefully examined.
Characteristics and source apportionment of PM2.5 under the dual influence of the Spring Festival and the COVID-19 pandemic in Yuncheng city - Based on the online and membrane sampling data of Yuncheng from January 1st to February 12th, 2020, the formation mechanism of haze under the dual influence of Spring Festival and COVID-19 (Corona Virus Disease) was analyzed. Atmospheric capacity, chemical composition, secondary transformation, source apportionment, backward trajectory, pollution space and enterprise distribution were studied. Low wind speed, high humidity and small atmospheric capacity inhibited the diffusion of air pollutants….